CDER 2005 NME Approvals: Glass Half Full At Third Quarter Mark?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s drug review center has approved just over half as many new molecular entities in the first three quarters of 2005 as it approved in the same time period of the preceding year.
You may also be interested in...
Lucky 13? Pace of 2006 CDER NME Approvals Bests 2005
New molecular entity and novel biologic approvals appear to be rebounding from 2005’s low point, an analysis of CDER approvals in 2006 to date suggests.
Significant Pending Applications With Fourth-Quarter User Fee Goals
Significant Pending Applications With Fourth-Quarter User Fee Goals
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011